GlassScriptPhysician profile
Kazi M Hassan
NPI 1801909296
$1,218.58
in general payments reported to CMS, 2019-2025
12 companies · $509 in 2025
The $509 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $33.51 · 2021: $41.11 · 2022: $56.34 · 2023: $154 · 2024: $425 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735 · Travel and Lodging: $184 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $734.72 |
| Travel and Lodging | $183.76 |
| Education | $169.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $543.70 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Medtronic, INC. | $270.07 | 2022-2025 | Intellis Adaptivestim |
| Scilex Pharmaceuticals INC. | $152.97 | 2021-2024 | Ztlido |
| Boston Scientific Corporation | $125.15 | 2020-2025 | Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $24.13 | 2023 | Proclaim |
| Si-Bone, INC. | $22.55 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $21.70 | 2025 | |
| Abbvie INC. | $15.45 | 2022 | |
| Averitas Pharma INC. | $14.93 | 2025 | Qutenza |
| Medtronic USA, INC. | $14.43 | 2020 | |
| Relievant Medsystems, INC. | $13.50 | 2023 | Intracept |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kazi Hassan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.